Risk Factors Update Summary

• Added detailed risks related to financial services industry disruptions, including specific examples of bank closures. This could lead to liquidity constraints and failures.
• Positive results achieved at the Month 30 endpoint for acoramidis low-dose infigratinib in Phase 3 trial.
• Accumulated deficit increased from $1.9 billion to $2 billion. This may impact future profitability.
• Entered into a Funding Agreement for $500 million, subject to FDA approval. Failure to meet conditions could impact funding and commercialization efforts.
• Failure to comply with Medicaid Drug Rebate program obligations may result in penalties and financial impact.
• Increased total employees from 392 to 556, a significant 41% increase. This expansion may impact infrastructure costs and operational efficiency.
• Authorized issuance of common stock increased from $350 million to $450 million, a $100 million rise. This may lead to dilution and impact stock price.
• Total consolidated indebtedness increased from $445 million to $455 million, a $10 million rise. This may affect cash flow and financial obligations.
• Increased total employees from 392 to 550, a significant 40% increase. This growth may affect operational efficiency and resource management.
• Principal selling party discontinued TRUSELTIQTM sales, affecting revenue generation and financial performance.
• Increased focus on cybersecurity risks to protect against potential breaches and data vulnerabilities.
• Changes in healthcare legislative measures may affect the company's operations and financial performance.
• Potential delays in clinical trials could lead to additional costs and impact the company's financials.
• Working capital decreased from $427 million to $333 million, a notable $94 million drop. This reduction may impact liquidity and financial flexibility.
• Clinical trial challenges may increase expenditures. Enrollment delays could impact study procedures and costs.
• Mention of disaster recovery and business continuity plans without specific details provided.
• Reference to increased volatility in stock price without quantification.